PURCHASE, NY, July 30, 2008 – Nutrition 21, Inc. (Nasdaq: NXXI) a developer and marketer of nutritional supplements that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and address chronic joint pain, today announced that its Iceland Health Omega-3 1000 mg softgel capsules achieved the highest rating designation - APPROVED – as part of a group of 50supplements, foods and beverages containing Omega-3 fatty acids independently tested by ConsumerLab.com.

Nutrition 21 voluntarily submitted their product to ConsumerLab.com for independent testing at a laboratory blinded to the product’s identity. Results of the test indicate that Iceland Health Omega-3 softgel capsules pass ConsumerLab.com’s quality standards for content, product purity, freshness, and potential contaminants (e.g., mercury, lead and PCBs) for omega-3 fish oil products.

Michael Zeher, chief executive officer of Nutrition 21 said, “We are pleased that our Iceland Health Omega-3 softgels have been judged to be pure and meet the content claims that we make on the product labeling. We are very proud of our tradition of providing products of unsurpassed quality within our Iceland Health segment. We take great care in formulating our products with the very best quality ingredients, and we are dedicated to continuing to do so perpetually.”

About ConsumerLab.com
ConsumerLab.com, LLC ("CL") is the leading provider of independent test results and information to help consumers and healthcare professionals evaluate health, wellness, and nutrition products. It publishes results of its tests at www.consumerlab.com — which receives over 3 million visits per year. It conducts an annual Survey of Vitamin & Supplement Users and publishes related reports. Its research is cited frequently in the media, books, and at medical meetings. As a certification company, CL enables companies of all sizes to have their products voluntarily tested for potential inclusion in its list of Approved Quality products and bear the CL Seal. Since its founding in 1999, CL has tested more than 2,100 products, representing over 350 different brands and nearly every type of popular supplement.

About Nutrition 21
Nutrition 21, Inc. (NASDAQ: NXXI), headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21’s portfolio of health and wellness brands include: Chromax®,  Core4Life Advanced Memory Formula™, Diabetes Essentials™, Iceland Health® Maximum Strength Omega-3 and Iceland Health® Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally.  For more information please visit http://www.nutrition21.com.
# # #

Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2007. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.